Evidence map›Paper›PMID 36976817›Full record

ArticleACS applied materials & interfaces2023

Feasibility of Coacervate-Like Nanostructure for Instant Drug Nanoformulation.

Geyunjian H Zhu, Mohammad Azharuddin, Bapan Pramanik, Karin Roberg, Sujoy Kumar Biswas, Padraig D'arcy, Meng Lu, Apanpreet Kaur, Alexander Chen, Ashis Kumar Dhara and 12 more

Abstract read
In one paragraph

Article in ACS applied materials & interfaces, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Geyunjian H ZhuDepartment of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge CB3 0AS, United Kingdom.ORCID 0000-0002-5410-9437
Mohammad AzharuddinDepartment of Biomedical and Clinical Sciences (BKV), Linkoping University, Linköping 58183, Sweden.
Bapan PramanikDepartment of Chemistry, Ben Gurion University of the Negev, Be'er Sheva 84105, Israel.ORCID 0000-0002-8860-2975
Karin RobergDepartment of Biomedical and Clinical Sciences (BKV), Linkoping University, Linköping 58183, Sweden.
Sujoy Kumar BiswasAIMP Laboratories, C86 Baishnabghata, Patuli Township, Kolkata 700094, India.
Padraig D'arcyDepartment of Biomedical and Clinical Sciences (BKV), Linkoping University, Linköping 58183, Sweden.ORCID 0000-0001-6671-7600
Meng LuDepartment of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge CB3 0AS, United Kingdom.
Apanpreet KaurDepartment of Chemical Engineering, Imperial College London, South Kensington Campus, London SW7 2AZ, United Kingdom.ORCID 0000-0002-0220-5849
Alexander ChenDepartment of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge CB3 0AS, United Kingdom.
Ashis Kumar DharaDepartment of Electrical Engineering, National Institute of Technology Durgapur, Durgapur 713209, West Bengal, India.
Alexandru ChivuDepartment of Surgical Biotechnology, Division of Surgery and Interventional Science, University College London, London NW3 2PF, United Kingdom.
Yunhui ZhuangDepartment of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge CB3 0AS, United Kingdom.ORCID 0000-0001-8941-3749
Andrew BakerDepartment of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge CB3 0AS, United Kingdom.
Xiewen LiuDepartment of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge CB3 0AS, United Kingdom.ORCID 0000-0002-4864-1080
David Fairen-JimenezDepartment of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge CB3 0AS, United Kingdom.ORCID 0000-0002-5013-1194
Bismoy MazumderDepartment of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge CB3 0AS, United Kingdom.
Rongjun ChenDepartment of Chemical Engineering, Imperial College London, South Kensington Campus, London SW7 2AZ, United Kingdom.ORCID 0000-0002-8133-5472
Clemens F KaminskiDepartment of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge CB3 0AS, United Kingdom.ORCID 0000-0002-5194-0962
Gabriele S Kaminski SchierleDepartment of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge CB3 0AS, United Kingdom.ORCID 0000-0002-1843-2202
Jorma HinkulaDepartment of Biomedical and Clinical Sciences (BKV), Linkoping University, Linköping 58183, Sweden.ORCID 0000-0003-1908-5609
Nigel K H SlaterDepartment of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge CB3 0AS, United Kingdom.
Hirak K PatraDepartment of Surgical Biotechnology, Division of Surgery and Interventional Science, University College London, London NW3 2PF, United Kingdom.ORCID 0000-0002-6142-5489

Funding

Medical Research Council G0902243Medical Research Council MR/K02292X/1Medical Research Council MR/T030968/1
6 · The paper itself

Abstract

Despite the enormous advancements in nanomedicine research, a limited number of nanoformulations are available on the market, and few have been translated to clinics. An easily scalable, sustainable, and cost-effective manufacturing strategy and long-term stability for storage are crucial for successful translation. Here, we report a system and method to instantly formulate NF achieved with a nanoscale polyelectrolyte coacervate-like system, consisting of anionic pseudopeptide poly(l-lysine isophthalamide) derivatives, polyethylenimine, and doxorubicin (Dox) via simple "mix-and-go" addition of precursor solutions in seconds. The coacervate-like nanosystem shows enhanced intracellular delivery of Dox to patient-derived multidrug-resistant (MDR) cells in 3D tumor spheroids. The results demonstrate the feasibility of an instant drug formulation using a coacervate-like nanosystem. We envisage that this technique can be widely utilized in the nanomedicine field to bypass the special requirement of large-scale production and elongated shelf life of nanomaterials.

Indexed as

NanoparticlesNanostructuresNeoplasmsCell Line, TumorDoxorubicinDrug CarriersDrug Delivery SystemsFeasibility StudiesHumansDoxorubicinDrug Carriers3D tumor spheroidscoacervate-like nanostructureinstant nanoformulationsnanomedicineself-assembly

Identifiers

PMID36976817
PMCPMC10103128

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.